These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 2174599)

  • 21. Efficacy of an inactivated vaccine for equine herpesvirus type 1 in a novel hamster model.
    Skinner GR; Davies J
    Intervirology; 2000; 43(1):27-35. PubMed ID: 10773735
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serological responses and clinical outcome after vaccination of mares and foals with equine herpesvirus type 1 and 4 (EHV-1 and EHV-4) vaccines.
    Bresgen C; Lämmer M; Wagner B; Osterrieder N; Damiani AM
    Vet Microbiol; 2012 Nov; 160(1-2):9-16. PubMed ID: 22633483
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The protective antigens of equine herpesvirus type 1.
    Papp-Vid G; Derbyshire JB
    Can J Comp Med; 1978 Apr; 42(2):219-26. PubMed ID: 208736
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Equine herpesvirus-1 strain KyA, a candidate vaccine strain, reduces viral titers in mice challenged with a pathogenic strain, RacL.
    Colle CF; Tarbet EB; Grafton WD; Jennings SR; O'Callaghan DJ
    Virus Res; 1996 Aug; 43(2):111-24. PubMed ID: 8864201
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The equine immune response to equine herpesvirus-1: the virus and its vaccines.
    Kydd JH; Townsend HG; Hannant D
    Vet Immunol Immunopathol; 2006 May; 111(1-2):15-30. PubMed ID: 16476492
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Monoclonal antibodies with neutralizing activity to equine herpesvirus 1.
    Shimizu M; Satou K; Nishioka N
    Arch Virol; 1989; 104(1-2):169-74. PubMed ID: 2538111
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of the efficacy of inactivated combination and modified-live virus vaccines against challenge infection with neuropathogenic equine herpesvirus type 1 (EHV-1).
    Goodman LB; Wagner B; Flaminio MJ; Sussman KH; Metzger SM; Holland R; Osterrieder N
    Vaccine; 2006 Apr; 24(17):3636-45. PubMed ID: 16513225
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Deletion of gene 52 encoding glycoprotein M of equine herpesvirus type 1 strain RacH results in increased immunogenicity.
    Osterrieder N; Seyboldt C; Elbers K
    Vet Microbiol; 2001 Aug; 81(3):219-26. PubMed ID: 11390105
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Equine herpesvirus 1 mutants devoid of glycoprotein B or M are apathogenic for mice but induce protection against challenge infection.
    Neubauer A; Beer M; Brandmüller C; Kaaden OR; Osterrieder N
    Virology; 1997 Dec; 239(1):36-45. PubMed ID: 9426444
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The characterization of equine herpes virus-1-infected cell polypeptides recognized by equine lymphocytes.
    Bridges CG; Ledger N; Edington N
    Immunology; 1988 Feb; 63(2):193-8. PubMed ID: 2832309
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interactions between equine herpesvirus type 1 and equine herpesvirus type 4: T cell responses in a murine infection model.
    Azmi M; Field HJ
    J Gen Virol; 1993 Nov; 74 ( Pt 11)():2339-45. PubMed ID: 8245851
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alterations in the equine herpesvirus type-1 (EHV-1) strain RacH during attenuation.
    Hübert PH; Birkenmaier S; Rziha HJ; Osterrieder N
    Zentralbl Veterinarmed B; 1996 Mar; 43(1):1-14. PubMed ID: 8919964
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterization of the major glycoproteins of equine herpesviruses 4 and 1 and asinine herpesvirus 3 using monoclonal antibodies.
    Crabb BS; Allen GP; Studdert MJ
    J Gen Virol; 1991 Sep; 72 ( Pt 9)():2075-82. PubMed ID: 1716650
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Equine herpesviruses 1 (EHV-1) and 4 (EHV-4)--epidemiology, disease and immunoprophylaxis: a brief review.
    Patel JR; Heldens J
    Vet J; 2005 Jul; 170(1):14-23. PubMed ID: 15993786
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Equine herpesvirus 1 infection in mares vaccinated with a live-virus rhinopneumonitis vaccine attenuated in cell culture.
    Eaglesome MD; Henry JN; McKnight JD
    Can Vet J; 1979 May; 20(5):145-7. PubMed ID: 226261
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization of an antigenic site on glycoprotein 13 (gC) of equid herpesvirus type-1.
    Sinclair R; Moult BJ; Mumford JA
    Arch Virol; 1993; 129(1-4):327-36. PubMed ID: 7682404
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An equine herpesvirus-1 gene 71 deletant is attenuated and elicits a protective immune response in mice.
    Marshall KR; Sun Y; Brown SM; Field HJ
    Virology; 1997 Apr; 231(1):20-7. PubMed ID: 9143298
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and duration of immunity of a combined equine influenza and equine herpesvirus vaccine against challenge with an American-like equine influenza virus (A/equi-2/Kentucky/95).
    Heldens JG; Pouwels HG; van Loon AA
    Vet J; 2004 Mar; 167(2):150-7. PubMed ID: 14975389
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Equine herpesvirus 1 glycoprotein D expressed in E. coli provides partial protection against equine herpesvirus infection in mice and elicits virus-neutralizing antibodies in the horse.
    Weerasinghe CU; Learmonth GS; Gilkerson JR; Foote CE; Wellington JE; Whalley JM
    Vet Immunol Immunopathol; 2006 May; 111(1-2):59-66. PubMed ID: 16473414
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and efficacy of a thymidine kinase negative equine herpesvirus-1 vaccine in young horses.
    Cornick J; Martens J; Martens R; Crandell R; McConnell S; Kit S
    Can J Vet Res; 1990 Apr; 54(2):260-6. PubMed ID: 2162730
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.